Recently, beyond improvement in both weight and glycemia control, new anti-diabetic drugs, such as glucagon-like peptide 1 receptor agonists (GLP-1RA) and sodium-dependent glucose co-transporter proteins 1 and 2 (SGLT1/2), were shown to be useful in reducing cardiovascular and kidney outcomes (death from cardiovascular disease, non-fatal myocardial infarction, non-fatal cerebral infarction, progressive decline in the eGFR of at least 50%, or end-stage kidney disease) in patients with diabetes with and without CKD (51–53). Here, GLP1R is linked to cardiovascular disorder.